A secondary analysis of the REPRIEVE trial followed 7507 people with HIV on effective antiretroviral therapy for a median of 5.6 years. Cancer incidence was 5.6 per 1000 person-years, with prostate, breast, lung and anal the leading cancers. Older age, residence in a high-income country and current smoking were associated with higher risk, whereas sex, body mass index and CD4-based measures were not.
Why it is interesting: In treated HIV, cancer risk now tracks age, region and smoking rather than immune status.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.